Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient interview study after NTLA-2002 treatment for hereditary angioedema
NL-OMON58260Not yet recruiting
- Sponsor
- Intellia Therapeutics
- Start
- Nov 2025
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Trial of lonvoguran, sponsored by Intellia Therapeutics. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
lonvoguran
Beyond the preview
Go deeper on NL-OMON58260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58260.